UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Annals of oncology, 2019-06, Vol.30 (6), p.970-976

2019

Volltextzugriff (PDF)

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Annals of oncology, 2018-12, Vol.29 (12), p.2371-2378

2018

Volltextzugriff (PDF)

Blockade of PD1 and TIM3 Restores Innate and Adaptive Immunity in Patients With Acute Alcoholic Hepatitis

Gastroenterology (New York, N.Y. 1943), 2015-03, Vol.148 (3), p.590-602.e10

2015

Volltextzugriff (PDF)

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial

Annals of oncology, 2015-11, Vol.26 (11), p.2300-2305

2015

Volltextzugriff (PDF)

Sustainable production of natural phenolics for functional food applications

Journal of functional foods, 2019-06, Vol.57, p.233-254

2019

Volltextzugriff (PDF)

Engineering Rhodosporidium toruloides with a membrane transporter facilitates production and separation of carotenoids and lipids in a bi-phasic culture

Applied microbiology and biotechnology, 2016-01, Vol.100 (2), p.869-877

2016

Volltextzugriff (PDF)

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

European journal of cancer (1990), 2017-02, Vol.72, p.S187-S188

2017

Volltextzugriff (PDF)

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

European journal of cancer (1990), 2017-02, Vol.72, p.S2-S2

2017

Volltextzugriff (PDF)

Process intensification writ large with microchannel absorption in nitric acid production

Chemical engineering science, 2017-09, Vol.169, p.140-150

2017

Volltextzugriff (PDF)

Microstructure and bonding behavior on the interface of an induction-melted Ni-based alloy coating and AISI 4140 steel substrate

Surface & coatings technology, 2010-07, Vol.204 (20), p.3173-3181

2010

Volltextzugriff (PDF)

4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial

European journal of cancer (1990), 2015-09, Vol.51, p.S708-S709

2015

Volltextzugriff (PDF)

A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platinum-based chemotherapy

European urology open science (Online), 2020-11, Vol.21, p.S92-S93

2020

Volltextzugriff (PDF)

Proteolytic enzyme loaded chitosan nanogel for efficient treatment of spinal disc herniation

New biotechnology, 2018-10, Vol.44, p.S98-S98

2018

Volltextzugriff (PDF)

Long-term efficacy of sequential vincristine, adriamycin, and dexamethasone (VAD) and bortezomib, thalidomide, and dexamethasone (VTD) as induction chemotherapy followed by high-dose melphalan with autologous stem cell transplantation (auto-SCT) and bortezomib consolidation: a follow-up study of KMM51

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e141-e142

2015

Volltextzugriff (PDF)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Annals of oncology, 2020-08, Vol.31 (8), p.1030-1039

2020

Volltextzugriff (PDF)

7124 POSTER Adjuvant Radiotherapy With or Without Chemotherapy in Patients With Stage lll/IV Transitional Cell Carcinoma of the Upper Urinary Tract And/or Positive Resection Margin

European journal of cancer (1990), 2011, Vol.47, p.S511-S512

2011

Volltextzugriff (PDF)

4 Oral: Casdatifan in patients (pts) with previously treated clear cell renal cell cancer (ccRCC) and other solid tumors; preliminary results from ARC- 20: A phase 1, open-label dose-escalation and expansion study

European journal of cancer (1990), 2024-10, Vol.211, p.114533, Article 114533

2024

Volltextzugriff (PDF)

Production of a potential collagenolytic protease by nejayote fermentation with Aspergillus oryzae

International journal of food science & technology, 2020-10, Vol.55 (10), p.3289-3296

2020

Volltextzugriff (PDF)

6156 POSTER Noninvasive Measurements From Computed Tomography and Laboratory Results Predict Hepatic Sinusoidal Injury Associated With Oxaliplatin-based Chemotherapy in Patients With Metastatic Colorectal Cancer

European journal of cancer (1990), 2011, Vol.47, p.S439-S439

2011

Volltextzugriff (PDF)

Trend in patient outcomes over time in a new tertiary surgical center in rural Haiti

Annals of global health, 2016-08, Vol.82 (3), p.532-532

2016

Volltextzugriff (PDF)

Comparative Assessment of the Effects of Gender-specific Heparan Sulfates on Mesenchymal Stem Cells

The Journal of biological chemistry, 2011-05, Vol.286 (20), p.17755-17765

2011

Volltextzugriff (PDF)

W120 Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients

Clinica chimica acta, 2022-05, Vol.530, p.S336-S336

2022

Volltextzugriff (PDF)

1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

Annals of oncology, 2024-09, Vol.35, p.S963-S964

2024

Volltextzugriff (PDF)

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

British journal of dermatology (1951), 2009-11, Vol.161 (5), p.1045-1051

2009

Volltextzugriff (PDF)

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Annals of oncology, 2017-11, Vol.28 (11), p.2754-2760

2017

Volltextzugriff (PDF)

1 – 25 von 1.881

Suche als RSS-Feed

Aktive Filter

KollektionJSTOR

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.522)
Mit Volltextzugriff
(1.673)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.158)
Life Sciences & Biomedicine
(593)
Technology
(412)
Physical Sciences
(369)
Humans
(309)
Physics
(254)
Biological And Medical Sciences
(204)
Engineering
(203)
Exact Sciences And Technology
(195)
Female
(190)
Male
(182)
Animals
(153)
Materials Science
(140)
Engineering, Electrical & Electronic
(131)
Fundamental And Applied Biological Sciences. Psychology
(128)
Adult
(101)
Materials Science, Multidisciplinary
(101)
Chemistry
(99)
Applied Sciences
(95)
Middle Aged
(84)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Blockade of PD1 and TIM3 Restores Innate and Adaptive Immunity in Patients With Acute Alcoholic Hepatitis

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial

Sustainable production of natural phenolics for functional food applications

Engineering Rhodosporidium toruloides with a membrane transporter facilitates production and separation of carotenoids and lipids in a bi-phasic culture

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study

Process intensification writ large with microchannel absorption in nitric acid production

Microstructure and bonding behavior on the interface of an induction-melted Ni-based alloy coating and AISI 4140 steel substrate

4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial

A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platinum-based chemotherapy

Proteolytic enzyme loaded chitosan nanogel for efficient treatment of spinal disc herniation

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

7124 POSTER Adjuvant Radiotherapy With or Without Chemotherapy in Patients With Stage lll/IV Transitional Cell Carcinoma of the Upper Urinary Tract And/or Positive Resection Margin

4 Oral: Casdatifan in patients (pts) with previously treated clear cell renal cell cancer (ccRCC) and other solid tumors; preliminary results from ARC- 20: A phase 1, open-label dose-escalation and expansion study

Production of a potential collagenolytic protease by nejayote fermentation with Aspergillus oryzae

6156 POSTER Noninvasive Measurements From Computed Tomography and Laboratory Results Predict Hepatic Sinusoidal Injury Associated With Oxaliplatin-based Chemotherapy in Patients With Metastatic Colorectal Cancer

Trend in patient outcomes over time in a new tertiary surgical center in rural Haiti

Comparative Assessment of the Effects of Gender-specific Heparan Sulfates on Mesenchymal Stem Cells

W120 Genotypic and phenotypic characteristics of hereditary leiomyomatosis and renal cell cancer syndrome in Korean patients

1598P Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Aktive Filter

Suchergebnisse filtern